Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel?
Habib
Ashraf S
AS
Gan
Tong J
TJ
D000932:Antiemetics / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004329:Droperidol / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D016527:Drug Costs; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D016568:Drugs, Generic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005060:Europe; D006220:Haloperidol / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D017294:Ondansetron / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
D000932:Antiemetics; D016568:Drugs, Generic; D017294:Ondansetron; D006220:Haloperidol; D004329:Droperidol